To allow for syngeneicity in the GPVI−/− mouse model and the use of two models (Fig. 6A), we engineered the mouse breast cancer AT341 cell line for stable luciferase expression to mirror the previously used 4T1 model (Fig. 1A) and allowed its use in a fully immunocompetent model. This evidence concerns the gene GP6 and breast carcinoma.